Investigating the Impact of Environmental Factors on the Transcriptomics Profile in Healthy Individuals
IMEN
1 other identifier
observational
8
1 country
1
Brief Summary
Changes in biology will be reflected by changes in the composition of Ribonucleic acid (RNA) in the blood. An example of that would be environmental changes, e.g. diet, acute illness, temperature. The main goal of this study is to study the impact of environmental changes in blood transcriptomics in healthy individuals over time.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for all trials
Started May 2023
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
May 9, 2023
CompletedFirst Submitted
Initial submission to the registry
September 6, 2023
CompletedFirst Posted
Study publicly available on registry
September 15, 2023
CompletedPrimary Completion
Last participant's last visit for primary outcome
February 29, 2024
CompletedStudy Completion
Last participant's last visit for all outcomes
February 29, 2024
CompletedSeptember 20, 2024
September 1, 2024
10 months
September 6, 2023
September 18, 2024
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
study the impact of environmental changes in blood transcriptomics
Changes in biology will be reflected by changes in the composition of Ribonucleic acid (RNA) in the blood. An example of that would be environmental changes, e.g. diet, acute illness, temperature.
12 months
Secondary Outcomes (1)
different sample collection materials
12 months
Study Arms (1)
healthy volunteers
Healthy status is defined by the absence of evidence of any active or chronic disease at the beginning of the study
Interventions
* 3 blood collections over a period of 6 weeks * V0 - Inclusion * V1 - 3 weeks ± 14 days * V2 - 3 weeks ± 14 days * 1 EDTA 4 ml tube, 1 PAXgene RNA tube 2,5 ml and drops of blood from finger-prick are taken at each visit * Clinical information obtained at each visit
Eligibility Criteria
healthy participants
You may qualify if:
- Voluntary, informed consent is obtained from the subject before enrollment in the study
- The subject is 18 years or older (≥18 years)
- Healthy participants, as declared by the subject
- Healthy status is defined by the absence of evidence of any active or chronic disease at the beginning of the study
- Available to participate for the planned duration of the study for which the screening is being done
You may not qualify if:
- The subject had any clinically significant disease
- Any clinically relevant history or the presence of e.g., respiratory, renal, hepatic, gastrointestinal, hematological, lymphatic, neurological, cardiovascular, psychiatric, etc. chronic disease
- Concomitant disease or condition that could interfere with, or treatment of which might interfere with, the conduct of the study, or that would, in the opinion of the investigator, pose an unacceptable risk to the subject in this study
- A condition in which repeated blood draws poses more than minimal risk for the subject such as hemophilia, other severe coagulation disorders or significantly impaired venous access
- In the opinion of the investigator, subject is at high risk of non-compliance and is unsuitable in any other way to participate in this study
- No informed consent obtained from the subject
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Centogene GmbH
Rostock, Mecklenburg-Vorpommern, 18055, Germany
Biospecimen
Blood
MeSH Terms
Interventions
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Tobias Böttcher, MD
CENTOGENE GmbH Rostock
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
September 6, 2023
First Posted
September 15, 2023
Study Start
May 9, 2023
Primary Completion
February 29, 2024
Study Completion
February 29, 2024
Last Updated
September 20, 2024
Record last verified: 2024-09
Data Sharing
- IPD Sharing
- Will not share